Evaluating a new PET imaging tracer for psychiatric disorders
Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311
This study is testing a new brain imaging method to see how it can help us understand brain function in people with schizophrenia, other psychotic disorders, cannabis use disorder, and healthy aging.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Yale University Academic / other |
| Locations | 1 site (New Haven, Connecticut) |
| Trial ID | NCT03995121 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of a novel SV2A PET tracer, [11C]APP311, in understanding synaptic density in individuals with schizophrenia, other psychotic disorders, and cannabis use disorder, as well as in healthy aging. Participants will undergo PET imaging alongside electroencephalography (EEG) assessments to evaluate sensory, perceptual, and cognitive functions. The study will focus on measuring event-related potentials (ERPs) and other EEG metrics to gather comprehensive data on brain activity related to these conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 65 who are either diagnosed with schizophrenia, other psychotic disorders, cannabis use disorder, or are healthy individuals.
Not a fit: Patients with MRI metal exclusions, claustrophobia, or less than 12 years of education may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of synaptic changes in psychiatric disorders, potentially leading to improved diagnostic and therapeutic strategies.
How similar studies have performed: While this approach is innovative, similar studies using PET imaging for psychiatric disorders have shown promise, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Willing and able to give voluntary written informed consent * Male and Female subjects, age 18 to 65 years, inclusive Exclusion Criteria: * MRI metal exclusions and claustrophobia. * Education completed is less than 12 years
Where this trial is running
New Haven, Connecticut
- Conneticut Mental Health Center — New Haven, Connecticut, United States (Recruiting)
Study contacts
- Study coordinator: Angerlyk Frytz, MD
- Email: angerlyk.frytz@yale.edu
- Phone: 203-974-7822
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.